Biotin-conjugated HCN1 antibodies are critical for studying HCN1’s role in neuronal excitability and neurological disorders:
Hippocampal Neuron Analysis: In mouse models of Hcn1 mutations (e.g., p.G391D, p.M153I), biotinylated secondary antibodies were used to detect reduced HCN1 protein levels in CA1 pyramidal neurons, correlating with diminished voltage sag and seizure susceptibility .
Subcellular Localization: Antibodies targeting the C-terminal region (e.g., AA 778–910) confirmed HCN1’s presence in presynaptic terminals and dendritic compartments, enabling studies on its role in synaptic plasticity .
Disease Modeling: Mutant HCN1-GD subunits exhibited impaired trafficking to axonal terminals, as shown via HA-tagged HCN1 and biotin-labeled detection systems .
High Specificity: The C-terminal epitope (AA 778–910) ensures minimal cross-reactivity, as validated in Western blot and IHC .
Versatile Detection: Biotin conjugation allows integration with streptavidin-HRP or fluorescent probes, enhancing sensitivity in:
ELISA Compatibility: Polyclonal variants enable quantitative analysis of HCN1 levels in serum or lysates .
N-Terminal vs. C-Terminal: Antibodies targeting the N-terminus (AA 6–24) may detect denatured HCN1 in WB, while C-terminal antibodies (AA 778–910) are optimal for native protein detection in IHC .
Species Reactivity: Human-specific polyclonal antibodies (e.g., A24483) lack cross-reactivity with rodent samples, requiring careful selection for interspecies studies .
Western Blot:
Immunohistochemistry: